PeptidePedia The community reference

Dipeptidyl peptidase-4 (revision 3)

Old revision·08:11, 8 Jul 2024·DrTitration

This is an old revision of this page, as it stood at 08:11, 8 Jul 2024, saved by DrTitration with the summary clarify that the incretin effect is defined by the oral–intravenous comparison. It may differ substantially from the current revision, and any error it contains may since have been corrected.
Dipeptidyl peptidase-4
AbbreviationDPP-4
Also known asCD26, adenosine deaminase-binding protein
EC numberEC 3.4.14.5
Topic infobox · conventions

Dipeptidyl peptidase-4 (DPP-4), also known as CD26, is a serine exopeptidase that removes the N-terminal two residues from peptides presenting proline or alanine in the second position. Both incretin hormones — Glucagon-like peptide-1 and Glucose-dependent insulinotropic polypeptide — carry alanine at position 2 and are therefore inactivated within minutes of secretion.[1]

The enzyme exists as a type II membrane protein on endothelial cells, epithelial cells and lymphocytes, and as a catalytically active soluble form in plasma. Cleavage of GLP-1 begins in the capillaries of the intestinal lamina propria, before the hormone reaches the portal vein, so that only a minority of secreted GLP-1 arrives at the systemic circulation intact.[2]

Catalytic action and substrate range

[edit]

DPP-4 cleaves the dipeptide His-Ala from the N-terminus of GLP-1(7–36)amide to yield GLP-1(9–36)amide. The truncated product binds the GLP-1 receptor with roughly two orders of magnitude lower affinity and behaves as a weak antagonist at pharmacological concentrations; whether it has independent cardiovascular activity remains an open question in the literature.[2]

The substrate range is wide. Substance P, neuropeptide Y, several chemokines and the incretins are all cleaved, and the enzyme also has non-catalytic functions as a co-stimulatory molecule on T cells and as a binding partner for adenosine deaminase. The breadth of this range is the reason inhibitor development required careful selectivity against the related enzymes DPP-8 and DPP-9.[1]

References

  1. ^ a b Deacon CF. "Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes." Frontiers in Endocrinology 10:80 (2019). DOI:10.3389/fendo.2019.00080. PMID 30828317.
  2. ^ a b Holst JJ. "The physiology of glucagon-like peptide 1." Physiological Reviews 87(4):1409–1439 (2007). PMID 17928588.